TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
葉昭廷Yeh, Chau-Ting
- 計畫主持人
- 執行臨床試驗年資 17 年 9 個月
-
chauting@cgmh.org.tw
發表文獻
18筆
1
Huang YH, Yeh CT. Anticancer Effects of Antidepressants in Hepatocellular Carcinoma Cells. Anticancer Res. 2023 Mar;43(3):1201-1206. doi: 10.21873/anticanres.16266. PMID: 36854516.
2
Lin CL, Liang KH, Hu CC, Chien CH, Chen LW, Chien RN, Lin YH, Yeh CT. A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma. Int J Mol Sci. 2023 Jan 14;24(2):1681. doi: 10.3390/ijms24021681. PMID: 36675198; PMCID: PMC9862766.
3
Lai MW, Chu YD, Hsu CW, Chen YC, Liang KH, Yeh CT. Multi-Omics Analyses Identify Signatures in Patients with Liver Cirrhosis and Hepatocellular Carcinoma. Cancers (Basel). 2022 Dec 29;15(1):210. doi: 10.3390/cancers15010210. PMID: 36612207; PMCID: PMC9818216.
4
Chu YD, Liu HF, Chen YC, Chou CH, Yeh CT. WWOX-rs13338697 genotype predicts therapeutic efficacy of ADI-PEG 20 for patients with advanced hepatocellular carcinoma. Front Oncol. 2022 Dec 2;12:996820. doi: 10.3389/fonc.2022.996820. PMID: 36530994; PMCID: PMC9756969.
5
Chu YD, Fan TC, Lai MW, Yeh CT. GALNT14-mediated O-glycosylation on PHB2 serine-161 enhances cell growth, migration and drug resistance by activating IGF1R cascade in hepatoma cells. Cell Death Dis. 2022 Nov 14;13(11):956. doi: 10.1038/s41419-022-05419-y. PMID: 36376274; PMCID: PMC9663550.
6
Lai MW, Chang YL, Cheng PJ, Chueh HY, Chang SC, Yeh CT. Absence of chronicity in infants born to immunized mothers with occult HBV infection in Taiwan. J Hepatol. 2022 Jul;77(1):63-70. doi: 10.1016/j.jhep.2022.01.030. Epub 2022 Feb 14. PMID: 35176439.
7
Chen WT, Lin SM, Lee WC, Wu TJ, Lin CC, Shen CH, Chang ML, Lin CL, Yeh CT. GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial. Hepatol Int. 2022 Feb;16(1):148-158. doi: 10.1007/s12072-021-10283-7. Epub 2022 Jan 4. PMID: 34982369.
8
Chu YD, Kee KM, Lin WR, Lai MW, Lu SN, Chung WH, Pang ST, Yeh CT. SYNE1 Exonic Variant rs9479297 Contributes to Concurrent Hepatocellular and Transitional Cell Carcinoma Double Primary Cancer. Biomedicines. 2021 Dec 2;9(12):1819. doi: 10.3390/biomedicines9121819. PMID: 34944636; PMCID: PMC8698502.
9
Liang KH, Chen SF, Lin YH, Chu YD, Lin YH, Lai MW, Lin CL, Yeh CT. Tenofovir Hampers the Efficacy of Sorafenib in Prolonging Overall Survival in Hepatocellular Carcinoma. Biomedicines. 2021 Oct 26;9(11):1539. doi: 10.3390/biomedicines9111539. PMID: 34829768; PMCID: PMC8614833.
10
Feng YY, Yu J, Huang YH, Lin YH, Yeh CT. The lipid peroxidation derived DNA adduct 帠-OHPdG levels in paraneoplastic liver tissues predict postoperative outcomes of hepatoma. J Cancer. 2021 May 13;12(13):4064-4074. doi: 10.7150/jca.56982. PMID: 34093810; PMCID: PMC8176245.
1
2
